Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Volpara to showcase comprehensive product offerings at NCoBC 2023 | ||
By: PR Newswire Association LLC. - 23 Mar 2023 | Back to overview list |
|
Volpara software transforms breast center workflow and eases cancer risk assessment LYNNWOOD, Wash., March 23, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection of cancer, is attending this year's National Consortium of Breast Centers (NCoBC) conference in Las Vegas to showcase its software advancements that are powering today's progressive breast centers. AI tools and education for federal breast density inform efforts
Volpara also offers Professional Services to help customers educate referrers and patients and to maximize the value of dense breast screening programs. Assess patient risk beyond breast cancer Risk Pathways also allows providers to look beyond breast cancer risk and identify the patient risk of colorectal, ovarian, endometrial, and pancreatic cancer. This enables greater partnership between the breast center and oncology departments, primary care providers, and OB/GYNs for true population health impact. Survey patients from home "Today's breast centers are in a unique position to reimagine how they deliver truly personalized care," said Volpara CEO Teri Thomas. "Volpara's software suite challenges the status quo, giving you smart technology to better engage patients, optimize how you work, and save more lives." Volpara's customer community goes digital To learn more about any of these product advancements, visit Volpara at NCoBC at booth #306 or request a virtual demo. References:
About Volpara Health (ASX: VHT) Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement. Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 17 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand. For more information, visit www.volparahealth.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/volpara-to-showcase-comprehensive-product-offerings-at-ncobc-2023-301779959.html SOURCE Volpara Health, Inc. |
||
|
||
Copyright 2023 PR Newswire Association LLC. | Back to overview list |